New Novavax Vaccine 89% Effective - Works Against UK Variant
Novavax has completed its phase 3 trials and is shown to be 89.3% effective against Covid-19. It is also 86% effective against the UK variant of the virus.
The vaccine will now go to the Medicine and Healthcare Products Regulatory Agency for approval. If approved, it will become the 4th vaccine to receive approval for emergency use alongside Pfizer, Moderna and AstraZeneca.
The UK has secured 60 million doses which will be produced in northeast England at a new production facility.
Photo Source: commons.wikimedia.org